A study published yesterday in Cancer Chemotherapy and Pharmacology reports that pharmacokinetic (PK) and pharmacodynamic (PD) data from a randomized, double-blind, phase 3 clinical study show similarity between mAbxience’s proposed rituximab biosimilar, RTXM83, and its reference, MabThera, using a population PK model approach.
A study published yesterday in Cancer Chemotherapy and Pharmacology reports that pharmacokinetic (PK) and pharmacodynamic (PD) data from a randomized, double-blind, phase 3 clinical study show similarity between mAbxience’s proposed rituximab biosimilar, RTXM83, and its reference, MabThera (also marketed as Ritxuan in the United States), using a population PK model approach.
The study was conducted in patients with diffuse large B-cell lymphoma (DLBCL). Patients (n = 251) received intravenous doses of 375 mg/m2 of either the biosimilar candidate plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (n = 127) or MabThera plus CHOP (n = 124).
PK similarity between the 2 products was assessed by comparing predicted serum concentratoins over time, derived from a population PK model, which “allows the use of sparse data to accurately calculate PK parameters,” according to the authors. Additionally, the schedule of treatment for DLBCL, which includes 6 treatment cycles that include 1 dose of rituximab every 21 days, allows for numerous PK measurements.
The primary PK endpoints of the study were area under the concentration—time curve (AUC) and the maximum serum concentration (Cmax), levels of CD20+ and CD19+ B cells in peripheral blood were assessed for the PD evaluation, and anti-drug antibodies (ADAs) were assessed.
The authors report the following:
The authors conclude that RTXM83 and MabThera have similar PK and PD and, to their knowledge, this study is the first to investigate the population PK of a rituximab biosimilar with a large sample size of patients, serum concentration, and multiple cycles of treatment.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.